SMARTWEALTH RUPIAH EQUITY INDOASIA FUND February 2019

BLOOMBERG: AZRPIAS:IJ

Investment Objective

The objective of this fund is to provide maximum long term investment yield.

Investment Strategy

To achieve the investment objective, this fund shall be invested 80 - 100% in equity instruments (directly through stocks and / or through equity mutual funds) and 0 - 20% in short-term instruments (such as deposits). Furthermore, the fund shall be invested in equity instruments in the Asia Pacific region, excluding Japan, not exceeding 20% of the fund.

Return Performance

Last 1-year period		-8.74%
Best Month	Oct-11	8.45%
Worst Month	Aug-11	-9.47%

Portfolio Breakdown

Equity		
Cash/Deposit		

Top Five Stocks Holding

Bank Central Asia
Bank Rakyat Indonesia
Hanjaya Mandala Sampoerna
Bank Mandiri Persero
Telekomunikasi Indonesia

Country Breakdown (Stock)

Indonesia
Philippines
Hongkong
South Korea
Malaysia
Singapore
Taiwan
Thailand

Key Fund Facts


Fund Size (in bn IDR)	IDR 755.94
Risk Profile	Aggressive
Launch Date	05 May 2011
Fund Currency	Indonesian Rupiah
Pricing Frequency	Daily
Bid-Offer Spread	5.00%
Management Fee	2.00% p.a.

Price per Unit	Bid	Offer
(As of Feb 28, 2019)	IDR 1,484.69	IDR 1,562.83

Managed by PT. Asuransi Allianz Life Indonesia

	1 Month	3 Months	6 Months	1 Year	3 Years	YTD	Since Inception
SmartWealth Rupiah Equity IndoAsia	-1.33%	5.19%	3.40%	-8.74%	21.69%	3.70%	56.28%
Benchmark*	-0.64%	6.61%	5.47%	-3.86%	37.77%	5.38%	64.01%

(New benchmark assessment as of May 2012; previously: Jakarta Composite Index (JCI))



Manager Commentary

The Asian market had an overall return of 0.23% for the month of February. Amongst Asian countries, the market top performers were Hong Kong (+5.85%) and Taiwan (+4.75%). The region bottom performers were the Philippines (-2.74%) and Korea (-1.87%). Hong Kong and Taiwan were top performers leading the region on trade talk expectations. Korea was a bottom performer for the month due to Korean stocks suffered a disappointing end of month due to the failed talks between the US and North Korea. Korea gave back previous month gains and the Korean won declined for month. The Philippines was a bottom performer due to exports unexpectedly fell and the peso declined relative to the US dollar.

93.06% Central Bureau Statistics of Indonesia (BPS) announced Feb 2019 deflation at -0.08% mom (vs consensus inflation -0.04%, +0.32% in Jan 2019). 6.94% On yearly basis, inflation was +2.57% yoy (vs consensus inflation +2.75%, +2.82% in Jan 2019). Core inflation was printed at +3.06% yoy (vs consensus inflation +3.06%, +3.06 in Jan 2019). The deflation in February 2019 was caused by the declining in chicken, egg and non-subsidized fuel price. In the Board of Governors' Meeting on 20th and 21st February 2019, Bank Indonesia kept the BI 7-day Reverse Repo Rate unchanged on 6.00%, while also maintaining the Deposit Facility (DF) and Lending Facility (LF) rates at 5.25% and 6.75% respectively. Rupiah appreciated by 7.65% +0.07% to 14,062/USD at end of February 2019 from 14,072/USD in previous month. Indonesia's trade balance recorded deficit amounting to USD 5.77% -1.159bn in January 2019 vs previous month deficit USD -1.102bn. This deficit was mainly contributed by declining in export growth, especially in 4.23% oil & gas side, on the back of declining in global crude oil price by -12% yoy. Oil and gas trade balance recorded deficit to USD -0.455bn in 3.79% January 2019, worse than deficit on December 2018 amounting to USD -0.219bn. Meanwhile, non-oil and gas trade balance in January 2019 3 74% recorded deficit USD -0.705bn, slightly better than the previous month which was deficit amounting to USD -0.883bn. This was occurred on the back of increasing in number of non-oil & gas export, such as: iron & steel and organic chemicals commodities. Indonesia's official foreign reserve as of Januari 2019 was at USD 120.1 billion, slightly lower than the December 2018 which stood at USD 120.7 billion. The decrement in the reserve assets in January 2019 was caused by government external debt repayment. 75.68%

0.00% The JCI ended the month lower at 6,443.35 (-1.37% MoM). Market laggards were ASII, BMRI, BBCA, INKP, and UNVR as they fell -15.38%, -4.36%, 8.57% -2.13%, -15.19% and -2.65% MoM respectively. The index and most markets across Asia weakened as investors started to be cautious on the US-3.91% China trade talks. Weaker export growth and auto sales in China, which experienced the first annual decline since 1990 also weighs on 1.16% sentiments across emerging Asia. On the domestic front, disappointing 4Q18 earnings result from Astra and MSCI outflow rebalancing also 0.03% played a part on declining risk appetite as foreign investors booked US237mn net outflows in Feb-19. In summary, FY19 Valuation has reverted 1.86% close to mean post the Jan rally at 15.5x P/E. Domestically we are keeping a close eye on the trade tariff developments and its ramification towards Indonesia's economic structure if any. Sector wise, the Miscellaneous Industries Sector was the worst performing sector during the week. 1.84% declining 11.91% MoM. Ticker wise, ASII (Astra International) and HDTX (Panasia Indo Resources) were the laggards, depreciating 15.38% and 10% MoM respectively. This was followed by the Agriculture Sector which dropped 8.4% WoW. Ticker wise, LSIP (Perusahaan Perkebunan London Sumatra Ind) and BWPT (Eagle High Plantations) posted 17.01% and 17% MoM losses respectively. On the other hand, the best sector during the month was the Trade, Service and Investment Sector, which recorded a gain of 3.42% MoM. Ticker wise, MPPA (Matahari Putra 4 Prima) and SKYB (Skybee) were the movers which rose 109.89% and 51.28% MoM respectively. ρ

procume: Smantweb/It Rupioh Equily IndeAsia Fund is a unit-linked fund offered by PT Asuronsi Allianz. Life Indonesia (Allianz). This fact sheet is prepared by Allianz. The information presented is for informational use only. The performance of the Fund is not guaranteed and the value of the units and the income from them may increase or decrease. Past returns and any forecast are not necessarily a guide to future genomera. Allianz does not warrant or make any representations regarding the use or the results of the use of the figure generated in terms of their corrections, concurse, licebility, or otherwise, You are devided to beek your financial consultant before moking any investment.

